Follow The Filings

INBX Inhibrx Biosciences Inc.

Health Care, filed as INHIBRX BIOSCIENCES INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2, sold by 1

  • 3 Owners
  • Max 0.5%
  • $110M
  • 2 new 1 reduce

In 2026 Q2 Nehal Chopra and James Silverman opened positions in Inhibrx Biosciences, while Andreas Halvorsen trimmed.

Who owns this now

Largest portfolio weights among holders, up to 0.5% (Nehal Chopra, Ratan Capital Management). Not free-float ownership.

  1. Nehal Chopra New 0.51%
  2. Andreas Halvorsen Reduce 0.30%
  3. James Silverman New 0.17%

Who owns INBX

Sorted by value, long equity only, as of 2026 Q2.

History
Andreas Halvorsen, Viking Global Investors 0.30% Reduce −21.8% 1,123,929 $106M History
James Silverman, Opaleye Management 0.17% New 0.17% 20,291 $1.9M History
Nehal Chopra, Ratan Capital Management 0.51% New 0.51% 16,612 $1.6M History

3 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by INBX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All INBX insider trades
  • $6.3M bought by 3 insiders
  • $279K sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Mark Lappe CEO
    Buy
    $849K 10,040 shares at $84.56 +6.3% to stake
    Traded Oct 14 Filed Oct 14
    ↗
  2. Mark Lappe CEO
    Buy
    $999K 10,000 shares at $99.88 +1.4% to stake
    Traded Sep 25–28 Filed Sep 28
    ↗
  3. Jon Faiz Kayyem Director
    Buy
    $500K 5,000 shares at $100.00 +1.2% to stake
    Traded Sep 23 Filed Sep 23
    ↗
  4. Jon Faiz Kayyem Director
    Buy
    $500K 5,000 shares at $100.00 +1.2% to stake
    Traded Sep 16 Filed Sep 17
    ↗
  5. Kimberly Manhard Director
    Sale
    $164K 1,500 shares at $109.03 17% of stake
    Traded Sep 11–15 Filed Sep 15
    ↗
  6. Kimberly Manhard Director
    Sale
    $115K 1,000 shares at $115.47 10% of stake
    Traded Sep 8–9 Filed Sep 10
    ↗
  7. Jon Faiz Kayyem Director
    Buy
    $568K 5,000 shares at $113.52 +1.2% to stake
    Traded Sep 8 Filed Sep 8
    ↗
  8. Mark Lappe CEO
    Buy
    $2.6M 25,000 shares at $105.82 +3.5% to stake
    Traded Sep 8 Filed Sep 8
    ↗
  9. Douglas Forsyth Director
    Buy
    $287K 2,500 shares at $114.65 +1.1% to stake
    Traded Sep 8 Filed Sep 8
    ↗
  10. Viking Global Investors LP 10% owner, +7 joint filers
    Sale
    $11.3M 350,000 shares at $32.25 77% of stake
    Traded Oct 7, 2025 Filed Oct 9, 2025
    ↗

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
8-K 7.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01,2.03,3.02,7.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2024 FY2025
Revenue $0.2M $1.3M
Net income $1.69B -$0.14B
Net margin * 843786.0% -10773.5%

Balance sheet

Metric FY2024 FY2025
Total current assets $160.4M $132.83M
Total non-current assets * $20.37M $13.65M
Total assets $180.77M $146.48M
Total current liabilities $40.73M $33.8M
Total non-current liabilities * $6.45M $104.69M
Total equity $133.58M $7.99M

Cash flow

Metric FY2024 FY2025
Cash from operations -$194.41M -$129.79M
Cash from investing -$2.6M -$0.028M
Cash from financing $71.68M $101.45M
Net change in cash -$125.33M -$28.38M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.